Von Willebrand disease in the Netherlands - Prospective study (WiN-Pro)
Recruiting
- Conditions
- Von Willebrand diseaseVWD1006447710005330
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1300
Inclusion Criteria
- Historically lowest VWF:Ag and/or VWF:Act and/or VWF:CB <= 0.30 IU/mL and/or
FVIII:C <= 0.40 IU/mL.
- Treatment at a Hemophilia treatment center in the Netherlands
- All types of VWD
- All ages
Exclusion Criteria
- Other bleeding disorders present
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The major-bleeding rate: bleeding that require blood transfusion, desmopressine<br /><br>or factor concentrates or bleeding that lead to death.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secundary outcomes are the minor-bleeding rate (all bleeding that do not fulfil<br /><br>the criteria for major-bleeding), bleeding during surgery, Von Willebrand<br /><br>factor levels and the ISTH-BAT score.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of VWF gene mutations are being investigated in the WiN-Pro observational study for Von Willebrand disease in the Netherlands?
How does the WiN-Pro trial compare the efficacy of desmopressin versus VWF concentrates in managing VWD subtypes in the Netherlands?
What biomarkers are used in the WiN-Pro study to stratify Von Willebrand disease patients and predict treatment response in the Netherlands?
What adverse events are reported in the WiN-Pro observational study of VWD patients receiving standard-of-care therapies in the Netherlands?
Are there combination therapies involving VWF concentrates and antifibrinolytic agents being evaluated in the WiN-Pro study for VWD management in the Netherlands?